公开(公告)号：EP1791807A1

公开(公告)日：2007-06-06

申请号：EP05782883.2

申请日：2005-08-29

申请人： Pfizer Products Incorporated

发明人： CLAFFEY, Michelle Marie Pfizer Global R & D ,  FLIRI, Anton Franz Josef Pfizer Global R & D ,  GALLASCHUN, Randall James Pfizer Global R & D ,  O'DONNELL, Christopher John Pfizer Global R & D

IPC分类号： C07C217/90 ,  C07D239/74 ,  C07D261/20 ,  C07D307/87 ,  C07D333/50 ,  C07D333/72 ,  A61K31/135 ,  A61K31/39 ,  A61K31/343 ,  A61K31/47 ,  A61K31/381

CPC分类号： A61K31/137 ,  A61K31/277 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/423 ,  A61K31/428 ,  C07C217/90 ,  C07C317/32 ,  C07C323/32 ,  C07C2602/08 ,  C07D239/74 ,  C07D261/20 ,  C07D307/87 ,  C07D333/50 ,  C07D333/72

摘要： This invention is directed to compounds of formula la, lb or Ic and to pharmaceutical compositions thereof: formula (Ia), formula (Ib), formula (Ic) or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.

摘要翻译： 本发明涉及式Ia，Ib或Ic的化合物及其药物组合物：式（Ia），式（Ib），式（Ic）或其前药以及药学上可接受的载体，其中R基团在 规范; 并且其中虚线表示可选的双键。 本发明还涉及治疗，诊断和预防与5HT受体有关的中枢神经系统疾病的方法，包括肥胖症，注意力缺陷障碍，偏头痛，抑郁症，癫痫症，焦虑症，阿尔茨海默病，戒断药物滥用， 疼痛，精神分裂症，压力相关障碍，惊恐障碍，睡眠障碍，恐怖症，强迫症，创伤后压力综合征，免疫系统抑制，压力诱导的胃肠功能障碍，压力诱发的心血管功能障碍和性功能障碍。